REFLUDAN [lepirudin (rDNA) for injection]: the first direct thrombin inhibitor FDA-approved for heparin induced thrombocytopenia (HIT)

Learn more about the benefits of REFLUDAN
This section describes the development of hirudin, a naturally occurring anticoagulant
This section contains REFLUDAN laboratory and clinical efficacy data
This section contains information regarding the safe administration of REFLUDAN for the treatment of heparin induced thrombocytopenia (HIT)
This section describes the dosage and administration of REFLUDAN in the treatment of heparin induced thrombocytopenia (HIT)
Heparin induced thrombocytopenia
A summary of pivotal trial data for REFLUDAN is covered in this section
This section provides access to a variety of resources to obtain in-depth information on heparin induced thrombocytopenia (HIT) and REFLUDAN
Find out what your peers are saying about heparin induced thrombocytopenia (HIT)...

©2007 Bayer Healthcare Pharmaceuticals Inc. All rights reserved.
H.I.T. BACK with REFLUDAN to protect life and limb
References
1.  REFLUDAN® [lepirudin (rDNA) for injection] Prescribing Information.
2.  Data on file, Berlex Laboratories, Inc.
3.  Greinacher A, Völpel H, Janssens U, et al, for the HIT Investigators Group. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;99:73-80. (HAT-1)
4.  Greinacher A, Janssens U, Berg G, et al, for the Heparin-Associated Thrombocytopenia Study (HAT) investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation. 1999;100:587-593. (HAT-2)
5.  Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res. 1994;74:1-23.


<< Back
Terms of Use      Privacy Policy      About Our New Company
Bayer Healthcare Pharmaceuticals